The Oregon Clinical & Translational Research Institute (OCTRI) is now accepting letters of intent to apply for its Biomedical Innovation Program. The Program cultivates and selects promising translational projects that develop new biomedical devices, diagnostics, and software. Via commercialization from academia to the marketplace, the objective is to move innovative technologies to clinical application, and thus to make a meaningful impact on human health. All applicants are strongly encouraged to take advantage of the Biomedical Innovation Program Q&A discussion led by OCTRI Director, Eric Orwoll, being held October 13th, 2014, from 12pm to 1pm in Mac Hall 1162. Representatives from OCTRI, and Technology Transfer & Business Development will be on hand to answer questions about the program and application process.
Deadline: Letters of intent due November 12, 2014
Amount: Up to $40,000 over one year
Eligibility: Principal investigators must fit OHSU eligibility requirements.
Don’t miss the Biomedical Innovation Program Q&A discussion!
October 13th, 2014, from 12pm to 1pm in Mac Hall 1162.
Critical elements of successful proposals will be a well-developed idea or vision for the end product and a collaboration between clinicians, scientists, and bioengineers; that collaboration will make possible the identification of a significant clinical problem, an innovative idea for a device or diagnostic to address the problem, bioengineering approaches for device or diagnostic development, voice of consumer studies, and early clinical trials.